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Purpose: To evaluate the role of prepared basic fibroblast growth factor (bFGF) and 
cytochrome c peroxidase (CCP) combination eyedrops in corneal epithelial healing of transgenic 
mice (B6(A)-Rperd12/J ) after excimer laser photoablation.
Materials and methods: In this prospective study, 216 eyes of 108 mice underwent bilateral 
photorefractive keratectomy. We considered 4 groups: A, B, C, and D. Group A received standard 
topical postoperative therapy with tobramycin, diclofenac, and dexamethasone eyedrops plus 
CCP at 3 drops per day for a week or until corneal re-epithelialization was achieved. Group B 
received standard topical postoperative therapy plus bFGF eyedrops and phosphate-buffered 
saline (PBS) 3 drops per day for a week or until corneal re-epithelialization was complete. 
In group C, 1 eye received standard topical postoperative therapy plus CCP eyedrops, bFGF 
eyedrops, and PBS 3 drops per day for a week or until corneal re-epithelialization was complete. 
Control eyes (group D) received a standard topical postoperative therapy plus placebo eyedrops. 
Mice were followed-up for a week from the day after the surgery to evaluate the rate of corneal 
re-epithelialization.
Results: Data were analyzed by ANOVA using the XLSTAT 2010 software. Eyes in group 
A, B, and C healed completely before the fifth postoperative day, achieving, respectively, a 
re-epithelialization time of 92 hours ± 10 SD, 90 hours ± 12 SD, and 86 hours ± 12 SD. Group 
D had a re-epithelialization time of 121 hours ± 8 SD (P , 0.05). No side effects or toxic 
effects were documented.
Conclusions: Results suggest that re-epithelialization after phototherapeutic keratectomy can 
benefit from topical therapy with CCP/bFGF combination eyedrops. Further clinical studies are 
needed to evaluate the long-term effectiveness of these eyedrops to prevent corneal haze.
Keywords: cytochrome c peroxidase, bFGF, corneal wound healing, excimer laser   photoablation, 
transgenic mice, refractive surgery
Introduction
Photorefractive keratectomy (PRK) is the application of energy in the ultraviolet 
range (UV) (193 nm wavelength), generated by an argon–fluoride excimer laser to the 
anterior corneal stroma to reshape its curvature and correct a refractive error (myopia, 
astigmatism and, more recently, hypermetropia). Phototherapeutic keratectomy (PTK) 
is the same application of energy but used to reshape anterior corneal stroma without 
correcting a refractive error. The physical process of remodeling the corneal stroma 
by UV high-energy photons is called photoablation. Complications of PRK include 
under-correction, over-correction, and induced astigmatism, which may be caused Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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by inadequate centralization or focusing during surgery. 
In fact, the success of PRK depends on uneventful corneal 
re-epithelialization and healing without postoperative com-
plications such as infection, keratitis, or corneal haze.
All side effects of PRK are direct or indirect consequences 
of corneal epithelial defect and ablation of the anterior 
stroma produced by the laser action. After PRK the cornea 
becomes more susceptible to several pathologic agents 
(chemical, physical, biological) with the possible appearance 
of infective or inflammatory events,1 because of corneal 
de-epithelialization, Bowman’s membrane destruction, 
and the exposure of the stroma, induced by photoablation. 
The cornea does not heal immediately but is covered by a 
discontinuous pseudomembrane, which is not enough to 
protect the underlying stroma. The release of cytokines, 
neuropeptides, and chemokines involved in the wound-
healing cascade contribute to a vicious cycle of phlogosis and 
to the onset of corneal pain.2 During the 24 to 48 hours after 
refractive surgery, most patients complain of painful corneal 
symptoms of various intensity because of the exposure of 
the damaged nerve endings.3
Another undesirable complication of superficial laser 
photoablation, as with PTK, is the development of corneal 
haze, with a frequency of 2.5% to 5%.4 These opacities 
appear to be a consequence of the destruction of Bowman’s 
membrane and the repair and replacement of stromal tissue 
post-PRK. Equilibrium of these factors in corneal wound 
healing is the main requirement to maintain corneal 
transparency. This equilibrium can be compromised by the 
acute injuries (chemical, inflammatory and infective) that 
may occur during postoperatively.5–7
According to a previous study by Esquenazi, after 
excimer photoablation laser-assisted sub-epithelial kerate-
ctomy (LASEK)-treated eyes showed less keratocyte apop-
tosis,   myofibroblast transformation, and upregulation in the 
synthesis of chondroitin sulfate than PRK-treated eyes. These 
differences may account for better visual acuity and less 
stromal haze in higher corrections in LASEK-treated eyes.8
Oxygen free radical-induced tissue damage following 
PRK is well documented.9–17
This study was performed to investigate the role of 
cytochrome c peroxidase (CCP) and basic fibroblast growth 
factor (bFGF) combination on the rate of corneal epithelial 
healing after PTK in transgenic mice. We decided to use 
these mice for our study because they did not present either 
genetic alterations in the cornea or corneal wound healing 
defects and presented a homogeneous cytology, structure, 
and corneal metabolism.
Cytochrome c peroxidase
First described in 1940,18 CCP is an enzyme located between 
the external and internal mitochondrial membrane of the 
yeast Saccharomyces cerevisiae. At this site, it catalyzes the 
oxidative reaction of ferrocytochrome c in the presence of 
hydrogen peroxide: H2O2 + 2 ferrocytochrome c + 2H+ → 2 
ferrocytochrome c + 2H2O. Several studies have shown that 
this enzyme is part of the anti-oxidation defense system that 
prevents intracellular accumulation of peroxide.18–21
CCP is a mitochondrial antioxidant that catalyzes the 
degradation of hydrogen peroxide (H2O2).22 It has a high 
affinity for 2 substrates: H2O2 (Km 4.5 × 10−6) and ferrocy-
tochrome c (Km 10−5).20
The activity of CCP is comparable to glutathione per-
oxidase activity in mammals.9 Glutathione peroxidase is the 
major component of the defense system against oxidative 
damage. It is predominantly present in corneal epithelium 
and endothelium. A significant decrease in glutathione 
peroxidase activity and concentration after mechanical 
epithelial removal has been reported; photoablation of the 
stroma decreases glutathione peroxidase activity more than 
epithelial scraping.23
H2O2 is physiologically present with a concentration from 
20 to 50 µM in corneal tissues. After PRK, the production of 
free radicals is even greater.23 Local inflammatory responses 
following excimer laser photoablation include infiltration of 
the corneal stroma by polymorphonuclear cells and produc-
tion of inflammatory mediators such as prostaglandin E2 and 
leukotriene B4.10 Ultraviolet radiation, polymorphonuclear 
cells infiltration, and thermal increase are the probable 
sources of reactive oxygen species after PRK. These degrade 
corneal collagen and proteoglycans and induce an aggres-
sive wound-healing response.10 The disequilibrium between 
the concentration of the free-radical scavengers and oxygen 
radicals produces inappropriate corneal wound healing, which 
is responsible for corneal haze and refractive regression.
Basic fibroblast growth factor
First described in 1978,18 bFGF is a member of the FGF 
family. bFGF has been show to have mitogenic, chemotactic, 
and angiogenic activity, promoting cell growth, differentia-
tion, and motility.19,20 bFGF is found in almost all tissues of 
mesodermal and neuroectodermal origin and also in tumors 
derived from these tissues. bFGF does not have a consensus 
signal sequence,21 and thus the mechanism of its release is not 
well understood. One line of thinking holds that bFGF may 
be released during cell injury. Many cells express bFGF only 
transiently and store it in a biologically inactive form.22–26Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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bFGF is a 288-residue protein with 12 antiparallel beta 
sheets.
FGF receptors are encoded by a gene family consisting of 
at least 4 receptor tyrosine kinases that transduce   important 
signals in a variety of developmental and physiological 
processes related to cell growth and differentiation, they are 
expressed on human bFGF-sensitive cells. Many different 
receptor phenotypes expressed in various cell types suggest a 
multifunctional role of bFGF: it stimulates the growth of fibro-
blasts, myoblasts, osteoblasts, neuronal cells, endothelial cells, 
keratinocytes, chondrocytes, and many other cell types.27–31
Production of growth factors by corneal cells and their 
presence in the tear fluid and aqueous humor is essential for 
maintenance and renewal of normal tissue in the anterior 
eye and the prevention of undesirable immune or angiogenic 
reactions. Growth factors also play a vital role in corneal 
wound healing, mediating the proliferation of epithelial and 
stromal tissue and affecting the remodeling of extracellular 
matrix. These functions depend on a complex interplay 
between growth factors of different types, the extracellular 
matrix, and regulatory mechanisms of the affected cells.32–36
The mechanism by which bFGF is released by the cells is 
not known. Levels of endogenous bFGF have been shown to 
increase at sites of injury, suggesting that its release and/or 
activation from intracellular sources and/or extracellular 
depots may be an integral part of the “rescue” effect.37–49
Materials and methods
The study included 216 eyes of 108 mice female B6(A)-
Rperd12/J mice, weighing 30 to 40 g. Mean age was 
24 weeks ± 0.2 SD. We decided to use this particular strain of 
mice because they have proved to have a wound healing and 
phlogosis response similar to that in humans. Furthermore, 
the bFGF receptor of these mice present the same affinity 
of human bFGF.
All mice had bilateral simultaneous PTK.
The central corneal thickness of mice. determined by 
performing a pachymetry exam (Pacline 2000 – Ultrasound 
pachymeter; Optikon, Rome, Italy), ranged from 280 µm 
to 300 µm. All mice suffering from ocular surface disease 
were excluded from the study. All animals were   maintained 
and handled in accordance with standard laboratory 
conditions and fed with a commercial pellet diet.
The experiment was performed according to animal care 
regulations and after permission had been granted by the local 
animal research ethics committee.
During the preoperative visit the following preopera-
tive examinations were performed under mixed   anesthesia 
with ketamine and xylazine (0.05% ketamine: 0.03 mL and 
0.023% xylazine 0.01 mL): slit-lamp biomicroscopy of the 
anterior segment (Haag-Streit 900, Berne, Switzerland); corneal 
pachymetry (Pacline 2000 –   Ultrasound Pachymeter; Optikon).
Excimer laser photoablation was performed using an 
argon fluoride excimer laser (Mel-70, Zeiss, Germany) 
emitting at 193 nm.
The corneal epithelium was removed by mechanical 
scraping using a hockey knife after the application of cotton tipped 
stick soaked in 70% alcohol for 30 seconds followed by a bal-
anced saline solution (BSS) wash. Photoablation was performed 
at the central cornea; an ablation rate of 1.5 µm per pulse was 
calculated. The repetition rate was 5 Hz, diameter of the ablation 
zone was 5.5 mm, and ablation depth was 45 to 50 µm.
Postoperative therapy consisted of a topical antibiotic 
(tobramycin 3 mg) eyedrops and diclofenac was applied topi-
cally 4 times a day for 7 days. Corticosteroid (dexamethasone 
1 mg) eyedrops were applied 3 times a day beginning from 
the seventh postoperative day.
For each mouse in group A, 1 eye was randomly 
assigned to the group that received standard therapy plus 
CCP; the fellow eye received standard therapy plus placebo 
(BSS 0.8%) 3 times a day until the cornea had completely 
recovered. The drug (CCP), commercially available in Italy, 
was administered for 7 days postoperatively or until corneal 
re-epithelialization was complete at a dosage of 2 drops 
3 times a day corresponding to 15,000 IU.
For each mouse of group B, 1 eye was randomly assigned 
to the group that received standard therapy plus bFGF; the 
fellow eye received standard therapy plus placebo (BSS 0.8%) 
3 times a day until the cornea had completely recovered. 
The drug was administered for 7 days postoperatively or 
until corneal re-epithelialization was complete at a dosage 
of 5 µg/10 µL PBS 3 times a day.
For each mouse of group C, 1 eye was randomly assigned 
to the group that received standard therapy plus CCP/bFGF 
combination; the fellow eye received standard therapy plus 
placebo (BSS 0.8%) 3 times a day until the cornea had com-
pletely recovered. The drug was administered for 7 days after 
surgery or until corneal re-epithelialization was complete at a 
dosage of 2 drops 3 times a day corresponding to 15,000 IU 
of CCP and 5 µg/10 µL PBS of bFGF 3 times a day.
Control eyes (group D) received a standard topical post-
operative therapy plus placebo eyedrops. Mice were followed 
up for a week from the day after the surgery to evaluate the 
rate of corneal re-epithelialization.
Mice were monitored daily for 1 week starting 24 hours 
postoperatively to evaluate the corneal re-  epithelialization rate. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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During the bio-microscopy examinations, video slit-lamp 
camera the corneal defects’ horizontal diameter, stained 
by fluorescein, was measured on days 1 through to 7 or 
until complete re-epithelialization. The diameter of the 
epithelial defect was analyzed by a computer-image ana-
lyzer (Adobe 5 software) and then measured with computer 
pachimetry. The measurements of corneal wounds in the 
2 groups were then compared. During follow-up slit-lamp 
bio-microscopy was performed to monitor corneal clarity.
The animals were sacrificed using sevoflurane inhalation 
anesthetic to determine a respiratory block after anesthesia 
with ketamine and xylazine (0.05% ketamine: 0.03 mL and 
0.023% xylazine 0.01 mL) after 30 days after the excimer 
laser photoablation.
histology
Mice eyes were fixed in 10% buffered formalin for 24 hours, 
thereafter samples were dehydrated in graded series of 
ethanol, cleared in xylene, and embedded in paraffin. Sections 
were stained with hematoxylin and eosin. Thick sections of 
paraffin-embedded tissue (5 µm) were cut and applied on 
1% silane pre-coated slides. All incubations were performed 
in a humidified chamber. Sections were counterstained in 
Mayer’s hematoxylin, dehydrated and mounted with DePeX 
Eukitt (Riedel de Haen, Seelze, Germany).
Statistical analysis
Data were evaluated by ANOVA using the XLSTAT 2010 
software.
Continuous variables are expressed as mean ± standard 
deviation (SD) and categorical variables are expressed as 
numbers and percentages.
Separate repeated measures ANOVA test models were 
used to assess differences in epithelial healing between 
groups A, B, C, and D (control group). We considered our 
results statistically significant at P , 0.05.
Mauchly’s sphericity test was used to examine the form of 
the error’s covariance matrix; in case of violation of assump-
tion, the Huynh–Feldt correction factor has been considered 
to obtain the adjusted P-values for each univariate F test 
involving time–interval effect.
Bonferroni correction was used for multiple post hoc 
comparisons.
Results
Eyes treated with CCP/bFGF combination (group C) showed 
a faster healing rate than eyes treated with standard therapy 
plus placebo (group D), eyes treated with CCP (group A), 
and eyes treated with bFGF (group B).
The mean defect diameter was as follows:
Day 1 postop: 4.41 mm ± 0.12 SD in CCP eyes 
(group A), 4.39 mm ± 0.11 SD in bFGF eyes (group B), 
4.31 mm ± 10 SD in CCP/bFGF combination eyes (group C), 
and 5.01 mm ± 0.11 SD in standard therapy plus placebo 
eyes (group D);
Day 2 postop: 3.04 mm ± 0.13 SD in CCP eyes 
(group A), 3.03 mm ± 0.10 SD in bFGF eyes (group B), 
3.00 mm ± 10 SD in CCP/bFGF combination eyes (group C), 
and 3.97 mm ± 0.12 SD in standard therapy plus placebo 
eyes (group D);
Day 3 postop: 1.40 mm ± 0.14 SD in CCP eyes 
(group A), 1.39 mm ± 0.13 SD in bFGF eyes (B group), 
1.33 mm ± 14 SD in CCP/bFGF combination eyes (group C), 
and 3.08 mm ± 0.11 SD in standard therapy plus placebo 
eyes (group D).
By day 4 postop, most mice in group A (90%), B (90%), 
and C (90%) had healed completely; treated eyes that 
had not healed had mean residual defect diameters of 
0.47 mm ± 0.13 SD, 0.39 mm ± 0.14 SD, 0.35 mm ± 0.13 SD, 
and 1.96 ± 0.14 mm in groups A, B, C, and D, respectively.
By day 5 postop, all eyes treated with CCP, bFGF, 
CCP/bFGF combination had completed the healing process; 
in standard therapy plus placebo eyes, the mean epithelial 
defect was 1.05 mm ± 0.15 SD.
By day 6 postop, the mean epithelial defect was 
0.30 mm ± 0.13 SD in group D.
By day 7 postop, all eyes in group D had completed the 
re-epithelialization process (Figure 1).
Mean defect diameter values changed across time 
intervals (days) (P , 0.0001). Group C mice mean defect 
diameters differed from those of groups A, B, and D mice 
(P , 0.0001). The pattern of differences between mean 
defect diameter values for groups A, B, C, and D mice 
changed at each time interval P , 0.0001 (Figure 1). 
Mean corneal   re-epithelization time in group A eyes was 
92 hours ± 10 SD, group B eyes 90 hours ± 12 SD, in group C 
eyes 86 hours ± 12 SD, and 121 hours ± 8 SD in group D 
eyes. Corneal   re-epithelization time differed significantly 
between group A, B, C, and D. The difference was greatest 
for group C, indicating that the bFGF/CCP combination 
is helpful in corneal re-epithelization after excimer laser 
  photoablation in mice.
The histology showed that the epithelial cell layer was 
intact in all eyes of all four groups, with preservation of Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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cellular polarity, phenotype, and total layer thickness after 
7 days. During the daily examinations no ocular or systemic 
adverse events were observed. No further effects of CCP and 
bFGF have been reported.
Discussion
Identification of factors that can aid corneal re-epithelization 
after epthelial injury, in this case induced by PRK, and avoid 
side effects related to corneal cicatrization can optimize 
surgical outcomes. Our hypothesis is that the CCP/bFGF 
combination, by synergistic activity, accelerates the healing 
rate after PTK. CCP breaks the peroxidative chain reaction 
involving organic and fatty acid hydroperoxidase and pre-
vents propagation of peroxide-dependent chain reactions 
that can lead to cell membrane lysis, and accelerate the 
healing rate. Moreover, CCP has a protective action against 
free-radical damage.
Also bFGF can reduce the harmful effects of reactive 
oxygen radicals after PTK and accelerates the healing rate. 
The therapeutic use of growth factors in corneal disease needs 
to be defined more clearly not only to accelerate and modulate 
cell proliferation in the corneal districts, but to avoid cicatri-
zation disease and corneal dullness caused by inflammation 
of the stroma. On the cornea, bFGF induces epithelium cell 
proliferation, by modulating synthesis of extracellular matrix 
components and corneal basal membrane.   Production of 
growth factors by corneal cells and their presence in the tear 
fluid and aqueous humor are essential for maintenance and 
renewal of normal tissue in the anterior eye and the prevention 
of undesirable immune or angiogenic reactions. Growth factors 
also play a vital role in corneal wound healing and affect the 
remodeling of the extracellular matrix.36 Moreover bFGF 
prevents haze increasing (transparency alteration activated 
by anomalous fibroblasts cell proliferation). Corneal damages 
usually cause an inflammation reaction and all phenomena 
correlated to phlogosis will occur. Growth factors are also 
released. Neovascularization of the cornea is a feared sequela 
to injuries and ulcers of the cornea, as well as to other types of 
inflammation. Neovascularization not only reduces vision, but 
can cause chronic irritation. We suggest that the CCP/bFGF 
combination is primarily involved in the healing process of 
corneal epithelium where there is an immediate inflammatory 
response instead of stromal wound healing.
One study has suggested that the degree and extent of 
keratocytes apoptosis varies with the type of overlying 
epithelial injury (PRK or laser in situ keratomileusis) and is 
influenced by changes in surgical technique or pharmaco-
logic therapy.30 This means that if rapid re-epithelialization 
occurs that preserves the epithelium corneal cytoarchitecture, 
the replacement of stroma with minimal cell apoptosis is 
guaranteed.
In our study the CCP/bFGF combination was efficient 
in decreasing corneal re-epithelialization time after PTK 
without significant ocular or systemic adverse events, and 
this corneal re-epithelialization was faster than with only 
topical therapy with bFGF or CCP.
Moreover, the standard treatment contains a cocktail 
of dexamethasone, diclofenac, and trobramicin; it is well 
established that the potent long-acting steroid dexametha-
sone inhibits wound healing and inflammation, significantly 
increases intraocular pressure, and upregulates superoxide 
dismutase. Diclofenac, a very potent nonsteroidal anti-
inflammatory drug, also delays wound healing and inhibits 
inflammation by completely inhibiting corneal prostaglandin 
formation. Both drugs significantly change normal wound 
healing. We were surprised that adding more drugs to an 
already complex mixture changed the rate of wound healing: 
growth factors such as bFGF partially possibly reversed the 
negative action of the dexamethasone on wound healing.
In conclusion, topical therapy with the CCP/bFGF 
combination is useful for reducing the harmful effects of 
reactive oxygen radicals after PTK and accelerates healing 
rate. Further investigations are required to confirm our results 
before clinical trials are begun.
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Figure 1 Average diameter of the defect of the corneal epithelium in eyes of group A 
(standard therapy plus cytochrome c peroxidase [CCP]), group B (standard therapy 
plus basic fibroblast growth factor [bFGF]), group C (standard therapy plus CCP/bFGF 
combination), and control group D (control; standard therapy plus placebo).
Notes: Standard therapy was postoperative therapy with tobramycin, diclofenac, 
and dexamethasone eyedrops.
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